Overview
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in gastric juice. Its sequence, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, was identified through screening of gastric mucosal proteins for cytoprotective activity. In vitro research has consistently demonstrated multi-pathway activity at the cellular level, making it one of the most studied research peptides in the recovery and cytoprotection category.
Nitric Oxide Pathway Modulation
The primary mechanism investigated in cell culture studies involves BPC-157's interaction with the nitric oxide (NO) system. Research in endothelial and vascular smooth muscle cells has shown that BPC-157 modulates eNOS (endothelial nitric oxide synthase) expression. Specifically, studies in HUVEC (human umbilical vein endothelial cell) models have observed upregulation of eNOS transcription and increased NO production at sub-micromolar concentrations. This NO-mediated signalling is proposed to underlie the cytoprotective and pro-angiogenic effects observed in in vitro wound models.
FAK and Paxillin Signalling
Multiple cell culture studies have examined BPC-157's effects on focal adhesion kinase (FAK) and its downstream effector paxillin. In fibroblast and endothelial cell models, BPC-157 treatment has been associated with phosphorylation of FAK at Tyr397, a key autophosphorylation site that activates downstream pro-survival and migratory signalling. Paxillin, a scaffolding protein at focal adhesion complexes, showed increased localisation at cell peripheries in treated fibroblasts, consistent with enhanced cell migration capacity in scratch-wound assays.
Cytoprotection in Oxidative Stress Models
In cell models of oxidative stress, typically induced by hydrogen peroxide or doxorubicin, BPC-157 pre-treatment has been shown to reduce markers of apoptosis including caspase-3 activation and cytochrome c release. In cardiac myocyte cell lines, BPC-157 at nanomolar concentrations attenuated anthracycline-induced mitochondrial membrane potential collapse, suggesting a role in mitochondrial membrane stabilisation. These findings are consistent with the peptide's proposed activity as a "stomach protein-derived cytoprotective factor."
Growth Factor Upregulation
EGR-1 (early growth response protein 1), a transcription factor involved in vascular and tissue repair gene expression, has been identified as upregulated in BPC-157-treated cell models. EGR-1 drives transcription of VEGF, TGF-β, and PDGF, growth factors central to angiogenesis and extracellular matrix remodelling. Cell supernatant analyses from BPC-157-treated fibroblast cultures have detected elevated VEGF concentrations, supporting a paracrine mechanism for the peptide's observed pro-angiogenic effects in co-culture tube-formation assays.
Research Limitations
The majority of published in vitro evidence for BPC-157 comes from a limited number of research groups, primarily in Croatia. Independent replication of specific mechanistic findings remains limited in the peer-reviewed literature. All mechanistic claims are based on cell culture and pre-clinical models. BPC-157 is not an approved drug and no clinical trials have established efficacy or safety in humans. All Stackpure BPC-157 is sold exclusively for in vitro research use.